Fox Run Management’s AnaptysBio ANAB Stock Holding History

Fox Run Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-27,796	Closed	-$517K	–	841
2025 Q1	$517K	Buy	+27,796	New	+$464K	0.08%	478

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Fox Run Management's ANAB Position: Q2 2025 in Review

Fox Run Management sold out of AnaptysBio (ANAB) in Q2 2025, closing a stake of 27,796 shares — an estimated $517K sold.

Fox Run Management first reported a position in ANAB in Q1 2025 and held it in 1 quarter. The position peaked at $517K in Q1 2025. 147 funds tracked by Wall St. Rank hold ANAB as of Q2 2025.

Fox Run Management reported no remaining AnaptysBio position as of Q2 2025 after selling out during the quarter.
Fox Run Management sold 27,796 AnaptysBio shares in Q2 2025, an estimated $517K.
Fox Run Management first reported a position in AnaptysBio in Q1 2025 and held it in 1 quarter.
Fox Run Management's AnaptysBio position peaked at $517K in Q1 2025.
147 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2025.

Based on Fox Run Management's 13F filing for Q2 2025, filed 6 Aug 2025.